Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 4, 2026, 10:01 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Period B Clear all
Active, not recruiting Phase 1 Interventional

BHV-7000 Responsive Neurostimulation System (RNS) Study

NCT07125261
View directory record Official record
Conditions
Epilepsy, Seizures
Interventions
BHV-700
Drug
Lead sponsor
Yale University
Other
Eligibility
18 Years to 75 Years
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Jun 11, 2026 · Synced Sep 4, 2026, 10:01 AM EDT
Completed Early Phase 1 Interventional Accepts healthy volunteers

Detection of Integrin avb6 in IPF, PSC, and COVID19 Using PET/CT

NCT03183570
View directory record Official record
Conditions
Idiopathic Pulmonary Fibrosis, Primary Sclerosing Cholangitis, Covid19 Pneumonia
Interventions
[18F]FP-R01-MG-F2
Drug
Lead sponsor
Stanford University
Other
Eligibility
18 Years and older
Enrollment
21 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2025
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Feb 3, 2025 · Synced Sep 4, 2026, 10:01 AM EDT
Completed Phase 3 Interventional Results available

Tralokinumab in Combination With Topical Corticosteroids for Moderate to Severe Atopic Dermatitis - ECZTRA 3

NCT03363854
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
Tralokinumab, Placebo
Drug
Lead sponsor
LEO Pharma
Industry
Eligibility
18 Years and older
Enrollment
380 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
21
States / cities
Birmingham, Alabama • Encinitas, California • Fountain Valley, California + 17 more
Source: ClinicalTrials.gov public record
Updated Mar 10, 2025 · Synced Sep 4, 2026, 10:01 AM EDT
Completed Phase 1 Interventional

A Study of the Pharmacokinetics and Immunologic Effects of Lipoic Acid in Multiple Sclerosis

NCT00676156
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
oral lipoic acid (LA), lipoic acid (LA) with fish oil and LA without fish oil, R lipoic acid
Drug
Lead sponsor
Oregon Health and Science University
Other
Eligibility
18 Years to 80 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2008
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Nov 5, 2012 · Synced Sep 4, 2026, 10:01 AM EDT
Not yet recruiting Phase 1Phase 2 Interventional

Epidermal Growth Factor Receptor Inhibition for Keratinopathies

NCT06545695
View directory record Official record
Conditions
Epidermolytic Ichthyosis, Palmoplantar Keratoderma, Pachyonychia Congenita
Interventions
Erlotinib
Drug
Lead sponsor
Northwestern University
Other
Eligibility
18 Years and older
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2027 – 2031
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Aug 2, 2026 · Synced Sep 4, 2026, 10:01 AM EDT
Terminated Phase 1 Interventional

Using Aflibercept Injection to Treat Blood Vessel Growth Over the Cornea

NCT01868360
View directory record Official record
Conditions
Corneal Neovascularization
Interventions
Subconjunctival aflibercept, Placebo: Standard of care only
Drug · Other
Lead sponsor
Balamurali Ambati
Other
Eligibility
18 Years and older
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Oct 6, 2015 · Synced Sep 4, 2026, 10:01 AM EDT
Completed Phase 1 Interventional

Study of XL888 With Vemurafenib for Patients With Unresectable BRAF Mutated Stage III/IV Melanoma

NCT01657591
View directory record Official record
Conditions
Melanoma
Interventions
XL888, Vemurafenib
Drug
Lead sponsor
H. Lee Moffitt Cancer Center and Research Institute
Other
Eligibility
18 Years and older
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2021
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Jan 18, 2023 · Synced Sep 4, 2026, 10:01 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Phase 1 Study on Bioavailability, Food Effect, and Drug-Drug Interaction of ALG-097558 Tablets in Healthy Volunteers

NCT06945276
View directory record Official record
Conditions
COVID-19
Interventions
ALG-097558, Dabigatran, Itraconazole, Placebo
Drug · Other
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 65 Years
Enrollment
51 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025
U.S. locations
1
States / cities
Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated May 17, 2026 · Synced Sep 4, 2026, 10:01 AM EDT
Completed Phase 2 Interventional Results available

Sunitinib or Cediranib for Alveolar Soft Part Sarcoma

NCT01391962
View directory record Official record
Conditions
Sarcoma, Alveolar Soft Part
Interventions
Cediranib, Sunitinib, Prochlorperazine, Promethazine, Benzodiazepine, Filgrastim, Sargramostim, Lomotil, Loperamide, Vitamin B6, Aquaphor, Acetaminophen, Levothyroxine, Warfarin
Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
16 Years to 120 Years
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2026
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Feb 1, 2026 · Synced Sep 4, 2026, 10:01 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Pharmacodynamic Study to Compare Acute Effects of Dihydroergotamine Mesylate (DHE) on Pulmonary Arterial Pressure

NCT01089062
View directory record Official record
Conditions
Healthy
Interventions
MAP0004, IV Placebo (Saline), Placebo Inhaler, IV Dihydroergotamine Mesylate (DHE)
Drug
Lead sponsor
Allergan
Industry
Eligibility
18 Years to 45 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Jan 8, 2014 · Synced Sep 4, 2026, 10:01 AM EDT
Completed Phase 2 Interventional

A Study of AND017 to Treat Anemia in Non-dialysis-Dependent Chronic Kidney Disease (NDD-CKD) Patients

NCT05035641
View directory record Official record
Conditions
Renal Anemia
Interventions
AND017, Placebo
Drug
Lead sponsor
Kind Pharmaceuticals LLC
Industry
Eligibility
20 Years to 74 Years
Enrollment
113 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
7
States / cities
Northridge, California • Winter Park, Florida • Shreveport, Louisiana + 4 more
Source: ClinicalTrials.gov public record
Updated Oct 3, 2023 · Synced Sep 4, 2026, 10:01 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Study to Compare Two Different Forms of PF-07081532 in Adults Who Are Overweight or Obese

NCT05677867
View directory record Official record
Conditions
Overweight, Obesity
Interventions
Formulation A (PF-07081532 20 mg plus 60 mg), Formulation B (PF-07081532 80 mg)
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Aug 8, 2024 · Synced Sep 4, 2026, 10:01 AM EDT
Active, not recruiting Phase 2 Interventional

Chemotherapy (DA-EPOCH+/-R) and Targeted Therapy (Tafasitamab) for the Treatment of Newly-Diagnosed Philadelphia Chromosome Negative B Acute Lymphoblastic Leukemia

NCT05453500
View directory record Official record
Conditions
B Acute Lymphoblastic Leukemia, Philadelphia Chromosome Negative
Interventions
Cyclophosphamide, Doxorubicin, Etoposide, Prednisone, Rituximab, Tafasitamab, Vincristine, Bone Marrow Aspiration, Bone Marrow Biopsy, Computed Tomography, Lumbar Puncture, Biospecimen Collection
Drug · Biological · Procedure
Lead sponsor
University of Washington
Other
Eligibility
18 Years and older
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2031
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated May 10, 2026 · Synced Sep 4, 2026, 10:01 AM EDT
Active, not recruiting Phase 3 Interventional

A Phase 3 Study to Assess Efficacy Safety and Tolerability of Remibrutinib in Adult and Adolescent Patients With Moderate to Severe Hidradenitis Suppurativa

NCT06840392
View directory record Official record
Conditions
Hidradenitis Suppurativa
Interventions
Remibrutinib Dose A, Remibrutinib Dose B, Placebo 1, Placebo 2
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
12 Years to 100 Years
Enrollment
565 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
35
States / cities
Birmingham, Alabama • Gilbert, Arizona • Fremont, California + 30 more
Source: ClinicalTrials.gov public record
Updated Aug 20, 2026 · Synced Sep 4, 2026, 10:01 AM EDT
Active, not recruiting Phase 1 Interventional Accepts healthy volunteers

Nicotine Pouch Pharmacokinetics Abuse Liability

NCT07476144
View directory record Official record
Conditions
Smoking Behaviors
Interventions
Participants will place the pouch between their top lip and their gum for 30 minutes as per use instructions.
Drug
Lead sponsor
JT International SA
Industry
Eligibility
22 Years to 65 Years
Enrollment
55 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026
U.S. locations
2
States / cities
Knoxville, Tennessee • San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Aug 18, 2026 · Synced Sep 4, 2026, 10:01 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

OPEN LABEL, 2-PERIOD STUDY, TO COMPARE BIO-AVAILABILITY OF 2 DIFFERENT FORMULATIONS OF PF-05221304 IN HEALTHY ADULTS

NCT03871439
View directory record Official record
Conditions
Healthy
Interventions
PF-05221304 Formulation A, PF-05221304 Formulation B
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 55 Years
Enrollment
10 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated May 19, 2020 · Synced Sep 4, 2026, 10:01 AM EDT
Completed Not applicable Interventional

Using Smartphones to Provide Recovery Support Services

NCT02132481
View directory record Official record
Conditions
Substance Use Disorder (SUD), Recovery
Interventions
EMA Only, EMI Only, EMA+EMI, Neither - RSAU
Other
Lead sponsor
Chestnut Health Systems
Other
Eligibility
18 Years and older
Enrollment
401 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2021
U.S. locations
3
States / cities
Chicago, Illinois • Normal, Illinois
Source: ClinicalTrials.gov public record
Updated Jul 27, 2021 · Synced Sep 4, 2026, 10:01 AM EDT
Not listed Not applicable Interventional Accepts healthy volunteers

Mind-Body Interventions to Mitigate Effects of Media Use on Sleep in Early Adolescents

NCT04550507
View directory record Official record
Conditions
Sleep Initiation and Maintenance Disorders
Interventions
Mindful sensory awareness intervention, Mindful sensory awareness + mindful body awareness check-ins intervention
Behavioral
Lead sponsor
Seattle Children's Hospital
Other
Eligibility
11 Years to 14 Years
Enrollment
75 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2021
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Oct 25, 2020 · Synced Sep 4, 2026, 10:01 AM EDT
Recruiting Phase 2 Interventional

Single-Arm Comprehensive Ablative Bridging Irradiation I Prior to CD19 CAR-T In High-Risk R/R LBCL

NCT06104592
View directory record Official record
Conditions
Large B-cell Lymphoma, Relapsed Non-Hodgkin Lymphoma
Interventions
Comprehensive Ablative Bridging Irradiation (CABI), Chimeric Antigen Receptor T-Cell Therapy
Radiation · Biological
Lead sponsor
H. Lee Moffitt Cancer Center and Research Institute
Other
Eligibility
18 Years and older
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Mar 30, 2026 · Synced Sep 4, 2026, 10:01 AM EDT
Completed Phase 2 Interventional Results available

A Study Evaluating Targeted Therapies in Participants Who Have Advanced Solid Tumors With Genomic Alterations or Protein Expression Patterns Predictive of Response

NCT04632992
View directory record Official record
Conditions
Advanced Unresectable or Metastatic Solid Malignancy
Interventions
Entrectinib, Inavolisib, Alectinib, Ipatasertib, Atezolizumab, Trastuzumab Emtansine, Pertuzumab, Trastuzumab, and Hyaluronidase-zzxf, Tucatinib, Investigator's Choice of Chemotherapy, Paclitaxel, Tiragolumab, Pralsetinib
Drug
Lead sponsor
Genentech, Inc.
Industry
Eligibility
18 Years and older
Enrollment
252 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
38
States / cities
Anchorage, Alaska • Oro Valley, Arizona • Hot Springs, Arkansas + 33 more
Source: ClinicalTrials.gov public record
Updated Jan 7, 2025 · Synced Sep 4, 2026, 10:01 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Investigate the Pharmacokinetics and Safety of Beclomethasone Dipropionate Administered by Breath-Actuated Inhaler and Metered-Dose Inhaler in Healthy Adults

NCT02030457
View directory record Official record
Conditions
Pharmacokinetics
Interventions
Beclomethasone dipropionate BAI, Beclomethasone dipropionate MDI
Drug
Lead sponsor
Teva Branded Pharmaceutical Products R&D, Inc.
Industry
Eligibility
18 Years to 45 Years
Enrollment
72 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2014
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Nov 8, 2021 · Synced Sep 4, 2026, 10:01 AM EDT
Completed Phase 3 Interventional Results available

Study to Compare Tenofovir Alafenamide (TAF) Versus Tenofovir Disoproxil Fumarate (TDF) in Participants With Chronic Hepatitis B Infection Who Are Positive for Hepatitis B e Antigen

NCT01940471
View directory record Official record
Conditions
HBeAg-positive Chronic Hepatitis B
Interventions
TAF, TDF, TAF Placebo, TDF Placebo
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years and older
Enrollment
875 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2022
U.S. locations
15
States / cities
Los Angeles, California • Palo Alto, California • Pasadena, California + 10 more
Source: ClinicalTrials.gov public record
Updated Oct 9, 2023 · Synced Sep 4, 2026, 10:01 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Sunovion Growth Study Pediatric Subjects With Mild Asthma & Allergic Rhinitis

NCT01550471
View directory record Official record
Conditions
Asthma, Allergic Rhinitis
Interventions
Alvesco/Omnaris, QVAR/Beconase, Placebo/Placebo, Alvesco/Omnaris, Placebo/Placebo, QVAR/Beconase, QVAR/Beconase, Alvesco/Omnaris, Placebo/Placebo, QVAR/Beconase, Placebo/Placebo, Alvesco/Omnaris, Placebo/Placebo, Alvesco/Omnaris, QVAR/Beconase, Placebo/Placebo, QVAR/Beconase, Alvesco/Omnaris
Drug
Lead sponsor
West Penn Allegheny Health System
Other
Eligibility
6 Years to 15 Years
Enrollment
22 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2015
U.S. locations
2
States / cities
Green Tree, Pennsylvania • Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Nov 3, 2020 · Synced Sep 4, 2026, 10:01 AM EDT
Active, not recruiting Phase 3 Interventional

Study to Compare Axicabtagene Ciloleucel With Standard of Care Therapy as First-line Treatment in Participants With High-risk Large B-cell Lymphoma

NCT05605899
View directory record Official record
Conditions
High-risk Large B-cell Lymphoma (LBCL)
Interventions
Axicabtagene Ciloleucel, Cyclophosphamide, Fludarabine, Etoposide, Rituximab, Doxorubicin, Vincristine, Prednisone
Biological · Drug
Lead sponsor
Kite, A Gilead Company
Industry
Eligibility
18 Years and older
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2031
U.S. locations
32
States / cities
Birmingham, Alabama • Gilbert, Arizona • Phoenix, Arizona + 26 more
Source: ClinicalTrials.gov public record
Updated Apr 14, 2026 · Synced Sep 4, 2026, 10:01 AM EDT